Blosozumab
From Infogalactic: the planetary knowledge core
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | SOST |
Identifiers | |
CAS Number | 1132758-87-2 |
ATC code | none |
KEGG | D10094 |
Chemical data | |
Formula | C6462H9852N1684O2030S46 |
Molecular mass | 144.63 kg/mol |
(what is this?) (verify) |
Blosozumab binds SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1]
Blosozumab was developed by Eli Lilly and Company.
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
<templatestyles src="Asbox/styles.css"></templatestyles>
<templatestyles src="Asbox/styles.css"></templatestyles>
Categories:
- Chemical articles having calculated molecular weight overwritten
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Monoclonal antibody stubs
- Musculoskeletal system drug stubs
- Eli Lilly and Company